prikaz prve stranice dokumenta Catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus treated with rituximab: case report and a review of the literature
  Preuzmi
PDF 579.64 KB
Znanstveni rad - Prikaz slučaja
Catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus treated with rituximab: case report and a review of the literature
Acta Reumatológica Portuguesa, 40 (2015), 2; 169-175. urn:nbn:hr:105:578591
Šukara, Goran; Barešić, Marko; Sentić, Mirna; Brčić, Luka; Anić, Branimir

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Šukara, G., Barešić, M., Sentić, M., Brčić, L. i Anić, B. (2015). Catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus treated with rituximab: case report and a review of the literature. Acta Reumatológica Portuguesa, 40. (2), 169-175. Preuzeto s https://urn.nsk.hr/urn:nbn:hr:105:578591

Šukara, Goran, et al. "Catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus treated with rituximab: case report and a review of the literature." Acta Reumatológica Portuguesa, vol. 40, br. 2, 2015, str. 169-175. https://urn.nsk.hr/urn:nbn:hr:105:578591

Šukara, Goran, Marko Barešić, Mirna Sentić, Luka Brčić i Branimir Anić. "Catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus treated with rituximab: case report and a review of the literature." Acta Reumatológica Portuguesa 40, br. 2 (2015): 169-175. https://urn.nsk.hr/urn:nbn:hr:105:578591

Šukara, G., et al. (2015) 'Catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus treated with rituximab: case report and a review of the literature', Acta Reumatológica Portuguesa, 40(2), str. 169-175. Preuzeto s: https://urn.nsk.hr/urn:nbn:hr:105:578591 (Datum pristupa: 29.12.2024.)

Šukara G, Barešić M, Sentić M, Brčić L, Anić B. Catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus treated with rituximab: case report and a review of the literature. Acta Reumatológica Portuguesa [Internet]. 04.2015. [pristupljeno 29.12.2024.];40(2):169-175. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:578591

G. Šukara, M. Barešić, M. Sentić, L. Brčić i B. Anić, "Catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus treated with rituximab: case report and a review of the literature", Acta Reumatológica Portuguesa, vol. 40, br. 2, str. 169-175, Travanj 2015. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:578591. [Citirano: 29.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:578591
Podaci o radu
Naslov (engleski)Catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus treated with rituximab: case report and a review of the literature
AutorGoran Šukara
AutorMarko Barešić
AutorMirna Sentić
AutorLuka Brčić
AutorBranimir Anić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Catastrophic antiphospholipid syndrome (CAPS) is a rare, acute, life-threatening form of antiphospholipid syndrome. In the last several decades there has been a significant improvement in the treatment of patients with CAPS, but the overall mortality is still very significant. The use of rituximab has been reported in the treatment of refractory cases of CAPS but the data are still scarce and inconclusive. We report a case of 47-year old male patient with long standing SLE and secondary APS who presented with acute thromboembolic incident (partial thrombosis of superior mesenteric artery). During the first week of his hospitalization he met the criteria for probable CAPS. He was treated with anticoagulants, glucocorticoids, intravenous immunoglobulins and systemic antibiotics. Finally he was treated with rituximab. There was no response to the implemented treatment and he eventually died. Autopsy showed evidence of small vessel thrombosis in the lung microvasculature. With this the criteria for definitive CAPS were fulfilled. To our knowledge, at present time, this is the first ever reported case of definitive CAPS associated with SLE treated with rituximab. There is a great need for further investigation to evaluate the effectiveness of rituximab in treatment of CAPS.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Prikaz slučaja
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaActa Reumatológica Portuguesa
Brojčani podacivol. 40, br. 2, str. 169-175
p-ISSN0303-464X
URN:NBNurn:nbn:hr:105:578591
Datum objave publikacije2015-04
URL dokumentahttp://actareumatologica.pt/article_download.php?id=1093
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 08:37:12